Previous close | 15.50 |
Open | 15.50 |
Bid | 15.30 |
Ask | 15.80 |
Strike | 20.00 |
Expiry date | 2023-05-19 |
Day's range | 15.50 - 15.50 |
Contract range | N/A |
Volume | |
Open interest | 2 |
GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.
Glaxo (GSK) delivered earnings and revenue surprises of 8.47% and 4.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
GlaxoSmithKline has improved their forecasts for 2023 after results reveal strong sales of the pharmaceutical firm's shingles vaccine.